These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 20546830)

  • 21. Prime-Pull Immunization with a Bivalent M-Protein and Spy-CEP Peptide Vaccine Adjuvanted with CAF®01 Liposomes Induces Both Mucosal and Peripheral Protection from
    Ozberk V; Reynolds S; Huo Y; Calcutt A; Eskandari S; Dooley J; Mills JL; Rasmussen IS; Dietrich J; Pandey M; Good MF
    mBio; 2021 Feb; 12(1):. PubMed ID: 33622722
    [TBL] [Abstract][Full Text] [Related]  

  • 22. M-protein based vaccine induces immunogenicity and protection from
    Mills JS; Jayashi Flores CM; Reynolds S; Wun C; Calcutt A; Baker SB; Murugappan S; Depelsenaire ACI; Dooley J; Fahey PV; Forster AH; Pandey M; Good MF
    NPJ Vaccines; 2020; 5(1):74. PubMed ID: 32802413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy targeting the Streptococcus pyogenes M protein or streptolysin O to treat or prevent influenza A superinfection.
    Herrera AL; Van Hove C; Hanson M; Dale JB; Tweten RK; Huber VC; Diel D; Chaussee MS
    PLoS One; 2020; 15(6):e0235139. PubMed ID: 32574205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccine-Induced Th1-Type Response Protects against Invasive Group A
    Rivera-Hernandez T; Rhyme MS; Cork AJ; Jones S; Segui-Perez C; Brunner L; Richter J; Petrovsky N; Lawrenz M; Goldblatt D; Collin N; Walker MJ
    mBio; 2020 Mar; 11(2):. PubMed ID: 32156809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Variation, Indispensability, and Masking in the M protein.
    Ghosh P
    Trends Microbiol; 2018 Feb; 26(2):132-144. PubMed ID: 28867148
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective Longitudinal Analysis of Immune Responses in Pediatric Subjects After Pharyngeal Acquisition of Group A Streptococci.
    Hysmith ND; Kaplan EL; Cleary PP; Johnson DR; Penfound TA; Dale JB
    J Pediatric Infect Dis Soc; 2017 Jun; 6(2):187-196. PubMed ID: 28204534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Accelerating the development of a group A Streptococcus vaccine: an urgent public health need.
    Excler JL; Kim JH
    Clin Exp Vaccine Res; 2016 Jul; 5(2):101-7. PubMed ID: 27489799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlates of Protection for M Protein-Based Vaccines against Group A Streptococcus.
    Tsoi SK; Smeesters PR; Frost HR; Licciardi P; Steer AC
    J Immunol Res; 2015; 2015():167089. PubMed ID: 26101780
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protective immunogenicity of group A streptococcal M-related proteins.
    Dale JB; Niedermeyer SE; Agbaosi T; Hysmith ND; Penfound TA; Hohn CM; Pullen M; Bright MI; Murrell DS; Shenep LE; Courtney HS
    Clin Vaccine Immunol; 2015 Mar; 22(3):344-50. PubMed ID: 25630406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel live vector group A streptococcal emm type 9 vaccine delivered intranasally protects mice against challenge infection with emm type 9 group A streptococci.
    Wozniak A; García P; Geoffroy EA; Aguirre DB; González SA; Sarno VA; Dale JB; Salazar-Echegarai FJ; Vera A; Bueno SM; Kalergis AM
    Clin Vaccine Immunol; 2014 Sep; 21(9):1343-9. PubMed ID: 25056362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Staphylococcal and streptococcal superantigen exotoxins.
    Spaulding AR; Salgado-Pabón W; Kohler PL; Horswill AR; Leung DY; Schlievert PM
    Clin Microbiol Rev; 2013 Jul; 26(3):422-47. PubMed ID: 23824366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential coverage of a multivalent M protein-based group A streptococcal vaccine.
    Dale JB; Penfound TA; Tamboura B; Sow SO; Nataro JP; Tapia M; Kotloff KL
    Vaccine; 2013 Mar; 31(12):1576-81. PubMed ID: 23375817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Region specific and worldwide distribution of collagen-binding M proteins with PARF motifs among human pathogenic streptococcal isolates.
    Reissmann S; Gillen CM; Fulde M; Bergmann R; Nerlich A; Rajkumari R; Brahmadathan KN; Chhatwal GS; Nitsche-Schmitz DP
    PLoS One; 2012; 7(1):e30122. PubMed ID: 22253902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protective efficacy of group A streptococcal vaccines containing type-specific and conserved M protein epitopes.
    Penfound TA; Chiang EY; Ahmed EA; Dale JB
    Vaccine; 2010 Jul; 28(31):5017-22. PubMed ID: 20546830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population.
    Yoonim N; Olive C; Pruksachatkunakorn C; Pruksakorn S
    BMC Microbiol; 2006 Aug; 6():71. PubMed ID: 16895610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune response against M protein-conserved region peptides from prevalent group A Streptococcus in a North Indian population.
    Gupta VK; Sekhar S; Dhanda V; Toor D; Kumar R; Chakraborti A
    J Microbiol Immunol Infect; 2016 Jun; 49(3):352-8. PubMed ID: 25087198
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-based design of broadly protective group a streptococcal M protein-based vaccines.
    Dale JB; Smeesters PR; Courtney HS; Penfound TA; Hohn CM; Smith JC; Baudry JY
    Vaccine; 2017 Jan; 35(1):19-26. PubMed ID: 27890396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipid core peptide technology and group A streptococcal vaccine delivery.
    Olive C; Batzloff MR; Toth I
    Expert Rev Vaccines; 2004 Feb; 3(1):43-58. PubMed ID: 14761243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strategies in the development of vaccines to prevent infections with group A streptococcus.
    Good MF; Batzloff MR; Pandey M
    Hum Vaccin Immunother; 2013 Nov; 9(11):2393-7. PubMed ID: 23863455
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.